27 May 2024 - Eisai Korea said its monoclonal antibody treatment Leqembi (lecanemab) has received approval from the Ministry of Food and Drug Safety for the treatment of mild cognitive impairment and mild Alzheimer's disease.

This approval makes Korea the fourth country to approve Leqembi, following the US, Japan and China.

Read Korea Biomedical Review article